Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Oncology

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Oncology

22 trials tracked for Oncology: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 441 citations.

22Trials tracked

2Phase 3 & 4

0Recruiting

2With published results

Phase distribution

Phase 3 2 Phase 2 8 Phase 1 5 Other / NA 7

Phase 3 Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma Completed · 441 cited
Phase 3 QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas Completed · 164 cited
Phase 2 Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed
Phase 2 PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Completed
Phase 2 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) Completed
Phase 2 Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment Completed

Show 16 more trials

Phase 2 Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) Completed
Phase 2 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies Completed
Phase 2 Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study Completed
Phase 2 A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma Completed
Phase 1 Study of Avelumab-M3814 Combinations Completed
Phase 1 Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies Completed
Phase 1 A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291 Completed
Phase 1 Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function Completed
Phase 1 A Study of LAM-003 in Patients With Acute Myeloid Leukemia Completed
N/A Feasibility of Adapted Physical Activity Based on a Walking Platform in Hospitalized Old Patients for Cancer Completed
N/A Giving Information Systematically and Transparently in Lung and GI Cancer Phase 1 Completed
N/A Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2 Completed
N/A Project Insight: Feasibility of a Breast Cancer Screening Decision Support Tool Completed
N/A SPARK Symptom Screening and Feedback to Providers Completed
N/A A Remote Evaluation of NAVIFY Oncology Hub Using Clinical Simulation Completed
N/A Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy Completed

Showing the 22 most-cited and recently-updated of 22 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Oncology: what the trials found

Clinical evidence demonstrates that Panitumumab is associated with specific efficacy and safety outcomes in relevant patient populations. In one study, Panitumumab showed a progression-free survival rate of 67% at week 17 and 55% at week 25, with corresponding disease control rates of 64% and 58% respectively ⁶. Another trial confirmed significant improvements in progression-free survival (p=0.0259) and local regional control over a 2-year period for patients treated with Panitumumab ⁷. Additionally, laboratory safety data indicated that the number of participants experiencing Grade 3 or higher laboratory abnormalities was low across study cohorts ⁸.

Interventions such as AMG 479 in combination with Gemcitabine were evaluated for survival outcomes in metastatic pancreatic adenocarcinoma; however, specific comparative efficacy values against placebo plus Gemcitabine were reported as nearly identical (7.0 vs 7.1; 7.2) ². Furthermore, the Oncolo-GIST intervention was evaluated and established in multiple clinical contexts [19, 20].

Recent results — preliminary, needs further review

E-602 is currently under investigation in a Phase 2 trial ³.
SUPLEXA is being evaluated in a Phase 1 study ¹¹.
The SPARK intervention was assessed using the SSPedi tool, showing symptom scores ranging from 10.2 to 13.2 across groups ¹⁷.
An adapted walking platform is currently under investigation ¹⁶.

For the clinician treating this condition

Panitumumab demonstrates significant progression-free survival and local regional control in specific clinical settings [6, 7].
Safety profiles for Panitumumab indicate a low incidence of high-grade laboratory abnormalities ⁸.

AI synthesis of 8 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

Questions about Oncology

Are PROTACs currently available as a treatment for my oncology condition?

PROTACs are not yet available as approved treatments for most oncology conditions, though one specific drug, vepdegestrant, is in clinical trials for advanced breast cancer.

Full answer →